Legislation allowing generic versions of medications made using biotechnology could result in dangerous treatments, a drugmaker and a senior U.S. senator said at a hearing yesterday. The proposed bill is flawed because it could permit companies to skip human trials before medications are approved, a representative of Johnson & Johnson, which makes biotech drugs, and Sen. Orrin Hatch, R-Utah, said at a hearing of the Senate health committee.